Hollings Home  
 
Richard R Drake, PhD
Professor of Cell and Molecular Pharmacology
College of Medicine
MUSC

Email: draker@musc.edu
 
       Print This Page
       
 
 


 

Richard R Drake, PhD

Return to Search Page  

Research Interest:

I am an experienced protein biochemist and glycobiologist, with particular expertise in tumor biology and biomarker discovery from clinical fluids and tissues related to urological cancers and other cancers. I have been part of an active translational research group and a member of the Early Detection Research Network for the past 12 years. I have directed several biospecimen-centric grants, including an NCI IMAT Cancer Sample Preparation R21, Proximal Prostate Fluids as Sources of Protein and miRNA Biomarkers of Prostate Cancer. As part of this grant, more than 1,000 prostatic fluid samples were collected, representing the entire benign and prostate cancer disease spectrum. I have also carried out a large number of contract and grant reviews related to biospecimens and biomarker research, including two contract reviews sponsored by the NCI Biorepositories and Biospecimen Research Branch. I have experience working directly with oncologists, surgeons, pathologists, basic researchers, and biorepository staff to effectively collect, manage, and utilize clinical sample resources. As Co-Director of the Biorepository & Tissue Analysis Shared Resource, I provide advice concerning experimental design and reviews results with investigators.

Honors:
Endowed Chair in Proteomics, SmartState Center of Economic Excellence

Positions:
Co-Director, Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, Medical University of South Carolina
Director, Proteomics Center, Medical University of South Carolina
Director, MUSC Enterprise-wide Tissue Biorepository Network, Medical University of South Carolina

Selected Publications:

1.Jones EE, Gao P, Smith CD, Norris JS, Drake RR. Tissue biomarkers of drug efficacy: case studies using a MALDI-MSI workflow. Bioanalysis. .7(20):2611-9, 2015.
View in: PubMed

2.Jones EE, Gao P, Smith CD, Norris JS, Drake RR. Tissue biomarkers of drug efficacy: case studies using a MALDI-MSI workflow. Bioanalysis. .7(20):2611-9, 2015.
View in: PubMed

3.Powers TW, Holst S, Wuhrer M, Mehta AS, Drake RR. Two-Dimensional N-Glycan Distribution Mapping of Hepatocellular Carcinoma Tissues by MALDI-Imaging Mass Spectrometry. Biomolecules. .5(4):2554-72, 2015.
View in: PubMed

4.Powers TW, Holst S, Wuhrer M, Mehta AS, Drake RR. Two-Dimensional N-Glycan Distribution Mapping of Hepatocellular Carcinoma Tissues by MALDI-Imaging Mass Spectrometry. Biomolecules. .5(4):2554-72, 2015.
View in: PubMed

5.Pallitto P, Ablonczy Z, Jones EE, Drake RR, Koutalos Y, Crouch RK, Donello J, Herrmann J. A2E and lipofuscin distributions in macaque retinal pigment epithelium are similar to human. Photochem Photobiol Sci. .14(10):1888-95, 2015. PMCID: PMC4589511
View in: PubMed

6.Drake RR, Jones EE, Powers TW, Nyalwidhe JO. Altered glycosylation in prostate cancer. Adv Cancer Res. .126:345-82, 2015.
View in: PubMed

7.Drake RR. Glycosylation and cancer: moving glycomics to the forefront. Adv Cancer Res. .126:1-10, 2015.
View in: PubMed

8.Drake RR, Ball L. Unique to this volume is the subsequent focus of individual chapters on what is known about glycosylation in relation to specific organ sites of cancer. Preface. Adv Cancer Res. .126:xiii-xiv, 2015.
View in: PubMed

9.Drake RR, Ball L. Unique to this volume is the subsequent focus of individual chapters on what is known about glycosylation in relation to specific organ sites of cancer. Preface. Adv Cancer Res. .126:xiii-xiv, 2015.
View in: PubMed

10.Rachidi S, Sun S, Wu BX, Jones E, Drake RR, Ogretmen B, Cowart LA, Clarke CJ, Hannun YA, Chiosis G, Liu B, Li Z. Endoplasmic reticulum heat shock protein gp96 maintains liver homeostasis and promotes hepatocellular carcinogenesis. J Hepatol. .62(4):879-88, 2014. PMCID: PMC4369194
View in: PubMed

11.Nowling TK, Mather AR, Thiyagarajan T, Hernández-Corbacho MJ, Powers TW, Jones EE, Snider AJ, Oates JC, Drake RR, Siskind LJ. Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis. J Am Soc Nephrol. .26(6):1402-13, 2014. PMCID: PMC4446878
View in: PubMed

12.Zhang J, Ye ZW, Gao P, Reyes L, Jones EE, Branham-O'Connor M, Blumer JB, Drake RR, Manevich Y, Townsend DM, Tew KD. Glutathione S-transferase P influences redox and migration pathways in bone marrow. PLoS One. .9(9):e107478, 2014. PMCID: PMC4162606
View in: PubMed

13.Powers TW, Neely BA, Shao Y, Tang H, Troyer DA, Mehta AS, Haab BB, Drake RR. MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays. PLoS One. .9(9):e106255, 2014. PMCID: PMC4153616
View in: PubMed

14.Jones EE, Dworski S, Canals D, Casas J, Fabrias G, Schoenling D, Levade T, Denlinger C, Hannun YA, Medin JA, Drake RR. On-tissue localization of ceramides and other sphingolipids by MALDI mass spectrometry imaging. Anal Chem. .86(16):8303-11, 2014. PMCID: PMC4139181
View in: PubMed

15.Von Roemeling CA, Marlow LA, Radisky DC, Rohl A, Larsen HE, Wei J, Sasinowska H, Zhu H, Drake R, Sasinowski M, Tun HW, Copland JA. Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration. Oncotarget. .5(14):5320-34, 2014. PMCID: PMC4170622
View in: PubMed

16.Von Roemeling CA, Marlow LA, Radisky DC, Rohl A, Larsen HE, Wei J, Sasinowska H, Zhu H, Drake R, Sasinowski M, Tun HW, Copland JA. Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration. Oncotarget. .5(14):5320-34, 2014. PMCID: PMC4170622
View in: PubMed

17.Medarova Z, Ghosh SK, Vangel M, Drake R, Moore A. Risk stratification of prostate cancer patients based on EPS-urine zinc content. Am J Cancer Res. .4(4):385-93, 2014. PMCID: PMC4106656
View in: PubMed

18.Medarova Z, Ghosh SK, Vangel M, Drake R, Moore A. Risk stratification of prostate cancer patients based on EPS-urine zinc content. Am J Cancer Res. .4(4):385-93, 2014. PMCID: PMC4106656
View in: PubMed

19.Baatz JE, Newton DA, Riemer EC, Denlinger CE, Jones EE, Drake RR, Spyropoulos DD. Cryopreservation of viable human lung tissue for versatile post-thaw analyses and culture. In Vivo. .28(4):411-23, 2014.
View in: PubMed

20.McDonald JA, Vadaparampil S, Bowen D, Magwood G, Obeid JS, Jefferson M, Drake R, Gebregziabher M, Hughes Halbert C. Intentions to donate to a biobank in a national sample of African Americans. Public Health Genomics. .17(3):173-82, 2014.
View in: PubMed

21.Jones EE, Powers TW, Neely BA, Cazares LH, Troyer DA, Parker AS, Drake RR. MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma. Proteomics. .14(7-8):924-35, 2014. PMCID: PMC4331029
View in: PubMed

22.Drake RR, Kislinger T. The proteomics of prostate cancer exosomes. Expert Rev Proteomics. .11(2):167-77, 2014.
View in: PubMed

23.Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, Benzine T, Madric K, Semmes OJ, Drake R, Esquela-Kerscher A. miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle. .13(2):227-39, 2013. PMCID: PMC3906240
View in: PubMed

24.Powers TW, Jones EE, Betesh LR, Romano PR, Gao P, Copland JA, Mehta AS, Drake RR. Matrix assisted laser desorption ionization imaging mass spectrometry workflow for spatial profiling analysis of N-linked glycan expression in tissues. Anal Chem. .85(20):9799-806, 2013. PMCID: PMC3969840
View in: PubMed

25.Cheng JC, Bai A, Beckham TH, Marrison ST, Yount CL, Young K, Lu P, Bartlett AM, Wu BX, Keane BJ, Armeson KE, Marshall DT, Keane TE, Smith MT, Jones EE, Drake RR, Bielawska A, Norris JS, Liu X. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. .123(10):4344-58, 2013. PMCID: PMC3784522
View in: PubMed

26.Nyalwidhe JO, Betesh LR, Powers TW, Jones EE, White KY, Burch TC, Brooks J, Watson MT, Lance RS, Troyer DA, Semmes OJ, Mehta A, Drake RR. Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression. Proteomics Clin Appl. .7(9-10):677-89, 2013. PMCID: PMC3969874
View in: PubMed

27.Leymarie N, Griffin PJ, Jonscher K, Kolarich D, Orlando R, McComb M, Zaia J, Aguilan J, Alley WR, Altmann F, Ball LE, Basumallick L, Bazemore-Walker CR, Behnken H, Blank MA, Brown KJ, Bunz SC, Cairo CW, Cipollo JF, Daneshfar R, Desaire H, Drake RR, Go EP, Goldman R, Gruber C, Halim A, Hathout Y, Hensbergen PJ, Horn DM, Hurum D, Jabs W, Larson G, Ly M, Mann BF, Marx K, Mechref Y, Meyer B, Möginger U, Neusüß C, Nilsson J, Novotny MV, Nyalwidhe JO, Packer NH, Pompach P, Reiz B, Resemann A, Rohrer JS, Ruthenbeck A, Sanda M, Schulz JM, Schweiger-Hufnagel U, Sihlbom C, Song E, Staples GO, Suckau D, Tang H, Thaysen-Andersen M, Viner RI, An Y, Valmu L, Wada Y, Watson M, Windwarder M, Whittal R, Wuhrer M, Zhu Y, Zou C. Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol Cell Proteomics. .12(10):2935-51, 2013. PMCID: PMC3790302
View in: PubMed

28.Roper SM, Zemskova M, Neely BA, Martin A, Gao P, Jones EE, Kraft AS, Drake RR. Targeted glycoprotein enrichment and identification in stromal cell secretomes using azido sugar metabolic labeling. Proteomics Clin Appl. .7(5-6):367-71, 2013. PMCID: PMC4331031
View in: PubMed

29.Principe S, Jones EE, Kim Y, Sinha A, Nyalwidhe JO, Brooks J, Semmes OJ, Troyer DA, Lance RS, Kislinger T, Drake RR. In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. Proteomics. .13(10-11):1667-71, 2013. PMCID: PMC3773505
View in: PubMed

30.Beckham TH, Lu P, Jones EE, Marrison T, Lewis CS, Cheng JC, Ramshesh VK, Beeson G, Beeson CC, Drake RR, Bielawska A, Bielawski J, Szulc ZM, Ogretmen B, Norris JS, Liu X. LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J Pharmacol Exp Ther. .344(1):167-78, 2012. PMCID: PMC3533418
View in: PubMed

31.Kim Y, Ignatchenko V, Yao CQ, Kalatskaya I, Nyalwidhe JO, Lance RS, Gramolini AO, Troyer DA, Stein LD, Boutros PC, Medin JA, Semmes OJ, Drake RR, Kislinger T. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics. .11(12):1870-84, 2012. PMCID: PMC3518113
View in: PubMed

32.Principe S, Kim Y, Fontana S, Ignatchenko V, Nyalwidhe JO, Lance RS, Troyer DA, Alessandro R, Semmes OJ, Kislinger T, Drake RR, Medin JA. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res. .11(4):2386-96, 2012. PMCID: PMC3642074
View in: PubMed

33.Hair PS, Wagner SM, Friederich PT, Drake RR, Nyalwidhe JO, Cunnion KM. Complement regulator C4BP binds to Staphylococcus aureus and decreases opsonization. Mol Immunol. .50(4):253-61, 2012.
View in: PubMed

34.Boggs SR, Cazares LH, Drake R. Characterization of a Staphylococcus aureus USA300 protein signature using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Med Microbiol. .61(Pt 5):640-4, 2012.
View in: PubMed

35.Drake RR, Boggs SR, Drake SK. Pathogen identifi cation using mass spectrometry in the clinical microbiology laboratory. J Mass Spectrom. .46(12):1, 2011.
View in: PubMed

36.Drake RR, Boggs SR, Drake SK. Pathogen identification using mass spectrometry in the clinical microbiology laboratory. J Mass Spectrom. .46(12):1223-32, 2011.
View in: PubMed

37.Lance RS, Drake RR, Troyer DA. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Expert Rev Anticancer Ther. .11(9):1341-3, 2011.
View in: PubMed

38.Dai C, Cazares LH, Wang L, Chu Y, Wang SL, Troyer DA, Semmes OJ, Drake RR, Wang B. Using boronolectin in MALDI-MS imaging for the histological analysis of cancer tissue expressing the sialyl Lewis X antigen. Chem Commun (Camb). .47(37):10338-40, 2011.
View in: PubMed

39.Cazares LH, Troyer DA, Wang B, Drake RR, Semmes OJ. MALDI tissue imaging: from biomarker discovery to clinical applications. Anal Bioanal Chem. .401(1):17-27, 2011.
View in: PubMed

40.Yang L, Nyalwidhe JO, Guo S, Drake RR, Semmes OJ. Targeted identification of metastasis-associated cell-surface sialoglycoproteins in prostate cancer. Mol Cell Proteomics. .10(6):M110.007294, 2011. PMCID: PMC3108840
View in: PubMed

41.Drake RR, Cazares LH, Jones EE, Fuller TW, Semmes OJ, Laronga C. Challenges to developing proteomic-based breast cancer diagnostics. OMICS. .15(5):251-9, 2011. PMCID: PMC3128487
View in: PubMed

42.Gatlin CL, White KY, Tracy MB, Wilkins CE, Semmes OJ, Nyalwidhe JO, Drake RR, Malyarenko DI. Enhancement in MALDI-TOF MS analysis of the low molecular weight human serum proteome. J Mass Spectrom. .46(1):85-9, 2011. PMCID: PMC3076319
View in: PubMed

43.Drake RR, Elschenbroich S, Lopez-Perez O, Kim Y, Ignatchenko V, Ignatchenko A, Nyalwidhe JO, Basu G, Wilkins CE, Gjurich B, Lance RS, Semmes OJ, Medin JA, Kislinger T. In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res. .9(5):2109-16, 2010. PMCID: PMC2869496
View in: PubMed

44.Britten RA, Mitchell S, Johnson AM, Singletary SJ, Keeney SK, Nyalwidhe JO, Karbassi ID, Lonart G, Sanford LD, Drake RR. The identification of serum biomarkers of high-let radiation exposure and biological sequelae. Health Phys. .98(2):196-203, 2010.
View in: PubMed

45.Drake RR. Glyco-Forum section Obituary: Alan D. Elbein (1933-2009). Glycobiology. .20(4):404-5, 2010.
View in: PubMed

46.Drake RR. Glyco-Forum section Obituary: Alan D. Elbein (1933-2009). Glycobiology. .20(4):404-5, 2010.
View in: PubMed

47.Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, Gutmann DH, McMahon M, Guerra C, Fagin JA, Yu B, Aoki Y, Neel BG, Balmain A, Drake RR, Nolan GP, Zenker M, Bollag G, Sebolt-Leopold J, Gibbs JB, Silva AJ, Patton EE, Viskochil DH, Kieran MW, Korf BR, Hagerman RJ, Packer RJ, Melese T. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A. .152A(1):4-24, 2010. PMCID: PMC4051786
View in: PubMed

48.Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ, Troyer DA. Molecular pathology of prostate cancer. Cancer Biomark. .9(1-6):441-59, 2010.
View in: PubMed

49.Mellmann A, Bimet F, Bizet C, Borovskaya AD, Drake RR, Eigner U, Fahr AM, He Y, Ilina EN, Kostrzewa M, Maier T, Mancinelli L, Moussaoui W, Prévost G, Putignani L, Seachord CL, Tang YW, Harmsen D. High interlaboratory reproducibility of matrix-assisted laser desorption ionization-time of flight mass spectrometry-based species identification of nonfermenting bacteria. J Clin Microbiol. .47(11):3732-4, 2009. PMCID: PMC2772641
View in: PubMed

50.Karbassi ID, Nyalwidhe JO, Wilkins CE, Cazares LH, Lance RS, Semmes OJ, Drake RR. Proteomic expression profiling and identification of serum proteins using immobilized trypsin beads with MALDI-TOF/TOF. J Proteome Res. .8(9):4182-92, 2009.
View in: PubMed

51.Cazares LH, Troyer D, Mendrinos S, Lance RA, Nyalwidhe JO, Beydoun HA, Clements MA, Drake RR, Semmes OJ. Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res. .15(17):5541-51, 2009.
View in: PubMed

52.Jing Y, Shaheen E, Drake RR, Chen N, Gravenstein S, Deng Y. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol. .70(10):777-84, 2009.
View in: PubMed

53.Jing Y, Shaheen E, Drake RR, Chen N, Gravenstein S, Deng Y. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol. .70(10):777-84, 2009.
View in: PubMed

54.Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ, Feliberti EC, Perry RR, Drake RR. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. .208(5):970-8; discussion 978-80, 2009.
View in: PubMed

55.Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ, Feliberti EC, Perry RR, Drake RR. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. .208(5):970-8; discussion 978-80, 2009.
View in: PubMed

56.White KY, Rodemich L, Nyalwidhe JO, Comunale MA, Clements MA, Lance RS, Schellhammer PF, Mehta AS, Semmes OJ, Drake RR. Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J Proteome Res. .8(2):620-30, 2009. PMCID: PMC2651839
View in: PubMed

57.Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, Given RW, Lance RS, Semmes OJ. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics. .72(6):907-17, 2009. PMCID: PMC2720443
View in: PubMed

58.Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, Given RW, Lance RS, Semmes OJ. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics. .72(6):907-17, 2009. PMCID: PMC2720443
View in: PubMed

59.Tracy MB, Chen H, Weaver DM, Malyarenko DI, Sasinowski M, Cazares LH, Drake RR, Semmes OJ, Tracy ER, Cooke WE. Precision enhancement of MALDI-TOF MS using high resolution peak detection and label-free alignment. Proteomics. .8(8):1530-8, 2008. PMCID: PMC2413415
View in: PubMed

60.Tracy MB, Chen H, Weaver DM, Malyarenko DI, Sasinowski M, Cazares LH, Drake RR, Semmes OJ, Tracy ER, Cooke WE. Precision enhancement of MALDI-TOF MS using high resolution peak detection and label-free alignment. Proteomics. .8(8):1530-8, 2008. PMCID: PMC2413415
View in: PubMed

61.Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC, Schraff S, Semmes OJ, Wadsworth JT, Drake RR. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope. .118(1):61-8, 2008.
View in: PubMed

62.Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC, Schraff S, Semmes OJ, Wadsworth JT, Drake RR. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope. .118(1):61-8, 2008.
View in: PubMed

63.Laronga C, Drake RR. Proteomic approach to breast cancer. Cancer Control. .14(4):360-8, 2007.
View in: PubMed

64.Laronga C, Drake RR. Proteomic approach to breast cancer. Cancer Control. .14(4):360-8, 2007.
View in: PubMed

65.Drake RR, Cazares L, Semmes OJ. Mining the low molecular weight proteome of blood. Proteomics Clin Appl. .1(8):758-68, 2007.
View in: PubMed

66.Shin S, Cazares L, Schneider H, Mitchell S, Laronga C, Semmes OJ, Perry RR, Drake RR. Serum biomarkers to differentiate benign and malignant mammographic lesions. J Am Coll Surg. .204(5):1065-71; discussion 1071-3, 2007.
View in: PubMed

67.Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A, Semmes OJ. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics. .5(10):1957-67, 2006.
View in: PubMed

68.Xiong Y, Bernardi D, Bratton S, Ward MD, Battaglia E, Finel M, Drake RR, Radominska-Pandya A. Phenylalanine 90 and 93 are localized within the phenol binding site of human UDP-glucuronosyltransferase 1A10 as determined by photoaffinity labeling, mass spectrometry, and site-directed mutagenesis. Biochemistry. .45(7):2322-32, 2006.
View in: PubMed

69.Xiong Y, Bernardi D, Bratton S, Ward MD, Battaglia E, Finel M, Drake RR, Radominska-Pandya A. Phenylalanine 90 and 93 are localized within the phenol binding site of human UDP-glucuronosyltransferase 1A10 as determined by photoaffinity labeling, mass spectrometry, and site-directed mutagenesis. Biochemistry. .45(7):2322-32, 2006.
View in: PubMed

70.Malyarenko DI, Cooke WE, Tracy ER, Drake RR, Shin S, Semmes OJ, Sasinowski M, Manos DM. Resampling and deconvolution of linear time-of-flight records for enhanced protein profiling. Rapid Commun Mass Spectrom. .20(11):1670-8, 2006.
View in: PubMed

71.Malyarenko DI, Cooke WE, Tracy ER, Drake RR, Shin S, Semmes OJ, Sasinowski M, Manos DM. Resampling and deconvolution of linear time-of-flight records for enhanced protein profiling. Rapid Commun Mass Spectrom. .20(11):1670-8, 2006.
View in: PubMed

72.Li AJ, Giuntoli RL, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller DS, Karlan BY. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol. .106(6):1304-8, 2005.
View in: PubMed

73.Li AJ, Giuntoli RL, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller DS, Karlan BY. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol. .106(6):1304-8, 2005.
View in: PubMed

74.Britten RA, Hardy C, Vlahou A, Gregory B, Giri PS, Drake R. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. Oncol Rep. .14(5):1323-30, 2005.
View in: PubMed

75.Britten RA, Hardy C, Vlahou A, Gregory B, Giri PS, Drake R. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. Oncol Rep. .14(5):1323-30, 2005.
View in: PubMed

76.Drake RR, Deng Y, Schwegler EE, Gravenstein S. Proteomics for biodefense applications: progress and opportunities. Expert Rev Proteomics. .2(2):203-13, 2005.
View in: PubMed

77.Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, Block TM, Marrero JA, Drake RR. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology. .41(3):634-42, 2005.
View in: PubMed

78.Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, Block TM, Marrero JA, Drake RR. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology. .41(3):634-42, 2005.
View in: PubMed

79.Drake RR, Cazare LH, Semmes OJ, Wadsworth JT. Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers. Expert Rev Mol Diagn. .5(1):93-100, 2005.
View in: PubMed

80.Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, Drake RR, Laronga C. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol. .11(10):907-14, 2004.
View in: PubMed

81.Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, Drake RR, Laronga C. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol. .11(10):907-14, 2004.
View in: PubMed

82.Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL, Drake RR, Vlahou A. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer. .100(9):1814-22, 2004.
View in: PubMed

83.Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL, Drake RR, Vlahou A. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer. .100(9):1814-22, 2004.
View in: PubMed

84.Comunale MA, Mattu TS, Lowman MA, Evans AA, London WT, Semmes OJ, Ward M, Drake R, Romano PR, Steel LF, Block TM, Mehta A. Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics. .4(3):826-38, 2004.
View in: PubMed

85.Laronga C, Becker S, Watson P, Gregory B, Cazares L, Lynch H, Perry RR, Wright GL, Drake RR, Semmes OJ. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers. .19(4-5):229-38, 2003. PMCID: PMC3851103
View in: PubMed

86.Laronga C, Becker S, Watson P, Gregory B, Cazares L, Lynch H, Perry RR, Wright GL, Drake RR, Semmes OJ. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers. .19(4-5):229-38, 2003. PMCID: PMC3851103
View in: PubMed

87.Mercer KE, Ahn CE, Coke A, Compadre CM, Drake RR. Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies. Protein Eng. .15(11):903-11, 2002.
View in: PubMed

88.Mercer KE, Ahn CE, Coke A, Compadre CM, Drake RR. Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies. Protein Eng. .15(11):903-11, 2002.
View in: PubMed